Bidness Etc | Gilead's Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C ... Stockhouse Study GS-US-334-0126 (Poster #1232), was a single-arm open-label Phase 2 trial in which patients with established recurrent HCV infection following liver transplantation received up to 24 weeks of therapy with Sovaldi plus RBV (escalating doses ... Gilead's Sovaldi Shows Efficacy & Safety In Chronic Hepatitis C Patients Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic ... |
